Discovery Laboratories Reports Surfaxin Manufacturing Issue; Drug Approval Delayed

WARRINGTON, Pa., April 24, 2006 (PRIMEZONE) -- Discovery Laboratories, Inc. (NasdaqNM:DSCO - News) today is announcing that analysis of ongoing stability data from Surfaxin(R) process validation batches indicates that certain stability parameters have not been achieved and, therefore, additional process validation batches will likely have to be produced. These process validation batches were previously manufactured as a requirement for Discovery's U.S. NDA regulatory approval and have been undergoing periodic stability testing. Discovery anticipates a potentially significant delay in the U.S. regulatory approval process for Surfaxin for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. At this time, it is not known whether this issue will have any impact on the Surfaxin European regulatory approval process.